What 5 Analyst Ratings Have To Say About Enanta Pharma
Portfolio Pulse from Benzinga Insights
Enanta Pharma (NASDAQ:ENTA) has received 5 analyst ratings in the last quarter, with 3 being bullish, 1 somewhat bullish, and 1 indifferent. The average price target is $28.8, which is significantly higher than the current price of $9.18, suggesting a substantial upside. However, this target has decreased by 20.55% from the previous target of $36.25. Analyst ratings are provided by financial specialists and can influence stock performance.
November 21, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enanta Pharma has a positive outlook from analysts with an average price target of $28.8, suggesting a significant upside from the current price of $9.18.
The average price target provided by analysts suggests a strong upside potential for Enanta Pharma's stock. The positive ratings, with the majority being bullish, indicate a favorable outlook which could lead to increased investor confidence and a potential rise in the stock price in the short term. However, the decrease in the average price target may temper expectations slightly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100